Compare BH & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BH | CTMX |
|---|---|---|
| Founded | 1934 | 2008 |
| Country | United States | United States |
| Employees | 2359 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.1M | 977.1M |
| IPO Year | N/A | 2015 |
| Metric | BH | CTMX |
|---|---|---|
| Price | $275.89 | $3.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.10 |
| AVG Volume (30 Days) | 57.1K | ★ 2.8M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | $597.67 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $234.92 | $1.72 |
| 52 Week High | $483.60 | $8.21 |
| Indicator | BH | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 39.49 |
| Support Level | $269.96 | $3.39 |
| Resistance Level | $321.70 | $3.91 |
| Average True Range (ATR) | 16.05 | 0.20 |
| MACD | 1.18 | 0.00 |
| Stochastic Oscillator | 55.14 | 39.76 |
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, and Oil and Gas Operations. Its restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The company also reports segment information for Maxim. The majority of revenue is derived from the Restaurant Operations Segment.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.